Stock EMBI SKYE BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/06/2024 BST 		5-day change 1st Jan Change
10.86 USD +3.63% Intraday chart for Skye Bioscience, Inc. +8.82% +299.26%
06-10 Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program CI
06-10 Skye Bioscience to stop eye disease drug development after failing mid-stage study RE

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
CI
Skye Bioscience to stop eye disease drug development after failing mid-stage study
RE
Skye Bioscience to discontinue development of eye disease treatment
RE
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
AQ
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index
CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index
CI
Skye Bioscience Uplists to The Nasdaq Global Market
AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K
PU
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating
MT
Skye Bioscience, Inc. announced that it has received $40 million in funding
CI
Skye Bioscience Announces $40 Million Private Placement Equity Financing
NE
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding
CI
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
AQ
Skye Bioscience Announces Board Changes
CI
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
AQ
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding
CI
Skye Bioscience to Present at Oppenheimer Investor Conference
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EMBI Stock
  4. News Skye Bioscience, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW